von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates

Background Apheresis platelet concentrates (APCs) are usually stored in citrated plasma at 22°C. The stability of coagulation proteins—von Willebrand factor (vWF), clotting factors (CFs), and their inhibitors—has often been described in association with the storage of thawed plasma. However, fewer d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transfusion (Philadelphia, Pa.) Pa.), 2014-03, Vol.54 (3), p.633-639
Hauptverfasser: Weiss, Dominik R., Franke, D., Strasser, Erwin F., Ringwald, Juergen, Zimmermann, Robert, Eckstein, Reinhold
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 639
container_issue 3
container_start_page 633
container_title Transfusion (Philadelphia, Pa.)
container_volume 54
creator Weiss, Dominik R.
Franke, D.
Strasser, Erwin F.
Ringwald, Juergen
Zimmermann, Robert
Eckstein, Reinhold
description Background Apheresis platelet concentrates (APCs) are usually stored in citrated plasma at 22°C. The stability of coagulation proteins—von Willebrand factor (vWF), clotting factors (CFs), and their inhibitors—has often been described in association with the storage of thawed plasma. However, fewer data are available regarding changes in APCs. Study Design and Methods We measured CF activities and inhibitors in APCs on the day of manufacture (Day 0) and on Days 4, 5, and 7. vWF was determined by measuring vWF antigen (vWF:Ag) and vWF ristocetin cofactor (vWF:RCo) and by multimer analysis. Results Twenty‐one PCs obtained by plateletpheresis were studied. Major changes were observed for Factor (F)VIII (37% loss of activity within 4 days), FV (20% within 4 days), and protein S (76% within 4 days). All other CF activities remained higher than 80% over the 7 days. Fibrinogen and the inhibitors antithrombin and protein C remained quite stable. FXI, FXII, and FXIII actually increased during storage (8, 11, and 12% within 4 days). vWF:Ag increased during storage of APCs by 2% per day, with a relative loss of vWF:RCo and high‐molecular‐weight multimers. Conclusion Even after 7 days of storage at 22°C, the hemostatic potential of the plasma content in APCs was roughly preserved. The increase in FXII antigen indicates that this CF may also be stored in platelets; however, this has not yet been described.
doi_str_mv 10.1111/trf.12304
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1507189353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3242132271</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3474-8aedc5d6a1ff94b63181c42d70ca0b13b1e0ead16fe42c5b1f99a2c97f9653bd3</originalsourceid><addsrcrecordid>eNpdkV9PFDEUxRuCkRV98AuQSYiJDwz09s90-mhQUEMg2azhsel0Wil0Z9a2q_Lt7bDLmtCX3t7zO21zD0LvAZ9CWWc5ulMgFLM9NANORU2k5PtohjGDGoCSA_QmpXuMMZEYXqMDQkUrJRYzZH6PQ3XrQ7Bd1ENfOW3yGE8qE8ac_fBz20gn1aTuun64852fhFJWenVno00-Vaugsw02V2YcjB1yLMf0Fr1yOiT7brsfoh8XXxbnX-urm8tv55-uak-ZYHWrbW9432hwTrKuodCCYaQX2GjcAe3AYqt7aJxlxPAOnJSaGCmcbDjtenqIPm7uXcXx19qmrJY-GRuCHuy4Tgo4FtBKymlBj1-g9-M6DuV3E8VZSzhnhTraUutuaXu1in6p46N6Hl8BPmwBnYwOrozQ-PSfa6nkDZueO9twf3ywjzsdsJryUyU_9ZSfWswvnoriqDcOn7L9u3Po-KAaQQVXt9eXan5N2--f5ULN6T8c4JyE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505482554</pqid></control><display><type>article</type><title>von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Weiss, Dominik R. ; Franke, D. ; Strasser, Erwin F. ; Ringwald, Juergen ; Zimmermann, Robert ; Eckstein, Reinhold</creator><creatorcontrib>Weiss, Dominik R. ; Franke, D. ; Strasser, Erwin F. ; Ringwald, Juergen ; Zimmermann, Robert ; Eckstein, Reinhold</creatorcontrib><description>Background Apheresis platelet concentrates (APCs) are usually stored in citrated plasma at 22°C. The stability of coagulation proteins—von Willebrand factor (vWF), clotting factors (CFs), and their inhibitors—has often been described in association with the storage of thawed plasma. However, fewer data are available regarding changes in APCs. Study Design and Methods We measured CF activities and inhibitors in APCs on the day of manufacture (Day 0) and on Days 4, 5, and 7. vWF was determined by measuring vWF antigen (vWF:Ag) and vWF ristocetin cofactor (vWF:RCo) and by multimer analysis. Results Twenty‐one PCs obtained by plateletpheresis were studied. Major changes were observed for Factor (F)VIII (37% loss of activity within 4 days), FV (20% within 4 days), and protein S (76% within 4 days). All other CF activities remained higher than 80% over the 7 days. Fibrinogen and the inhibitors antithrombin and protein C remained quite stable. FXI, FXII, and FXIII actually increased during storage (8, 11, and 12% within 4 days). vWF:Ag increased during storage of APCs by 2% per day, with a relative loss of vWF:RCo and high‐molecular‐weight multimers. Conclusion Even after 7 days of storage at 22°C, the hemostatic potential of the plasma content in APCs was roughly preserved. The increase in FXII antigen indicates that this CF may also be stored in platelets; however, this has not yet been described.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.12304</identifier><identifier>PMID: 23789907</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Hoboken, NJ: Blackwell Publishing Ltd</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Coagulation Factors - metabolism ; Blood Platelets - metabolism ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Humans ; Medical sciences ; Plateletpheresis ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; von Willebrand Factor - metabolism</subject><ispartof>Transfusion (Philadelphia, Pa.), 2014-03, Vol.54 (3), p.633-639</ispartof><rights>2013 American Association of Blood Banks</rights><rights>2015 INIST-CNRS</rights><rights>2013 American Association of Blood Banks.</rights><rights>2014 AABB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftrf.12304$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftrf.12304$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28395643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23789907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weiss, Dominik R.</creatorcontrib><creatorcontrib>Franke, D.</creatorcontrib><creatorcontrib>Strasser, Erwin F.</creatorcontrib><creatorcontrib>Ringwald, Juergen</creatorcontrib><creatorcontrib>Zimmermann, Robert</creatorcontrib><creatorcontrib>Eckstein, Reinhold</creatorcontrib><title>von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Background Apheresis platelet concentrates (APCs) are usually stored in citrated plasma at 22°C. The stability of coagulation proteins—von Willebrand factor (vWF), clotting factors (CFs), and their inhibitors—has often been described in association with the storage of thawed plasma. However, fewer data are available regarding changes in APCs. Study Design and Methods We measured CF activities and inhibitors in APCs on the day of manufacture (Day 0) and on Days 4, 5, and 7. vWF was determined by measuring vWF antigen (vWF:Ag) and vWF ristocetin cofactor (vWF:RCo) and by multimer analysis. Results Twenty‐one PCs obtained by plateletpheresis were studied. Major changes were observed for Factor (F)VIII (37% loss of activity within 4 days), FV (20% within 4 days), and protein S (76% within 4 days). All other CF activities remained higher than 80% over the 7 days. Fibrinogen and the inhibitors antithrombin and protein C remained quite stable. FXI, FXII, and FXIII actually increased during storage (8, 11, and 12% within 4 days). vWF:Ag increased during storage of APCs by 2% per day, with a relative loss of vWF:RCo and high‐molecular‐weight multimers. Conclusion Even after 7 days of storage at 22°C, the hemostatic potential of the plasma content in APCs was roughly preserved. The increase in FXII antigen indicates that this CF may also be stored in platelets; however, this has not yet been described.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation Factors - metabolism</subject><subject>Blood Platelets - metabolism</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Plateletpheresis</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>von Willebrand Factor - metabolism</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV9PFDEUxRuCkRV98AuQSYiJDwz09s90-mhQUEMg2azhsel0Wil0Z9a2q_Lt7bDLmtCX3t7zO21zD0LvAZ9CWWc5ulMgFLM9NANORU2k5PtohjGDGoCSA_QmpXuMMZEYXqMDQkUrJRYzZH6PQ3XrQ7Bd1ENfOW3yGE8qE8ac_fBz20gn1aTuun64852fhFJWenVno00-Vaugsw02V2YcjB1yLMf0Fr1yOiT7brsfoh8XXxbnX-urm8tv55-uak-ZYHWrbW9432hwTrKuodCCYaQX2GjcAe3AYqt7aJxlxPAOnJSaGCmcbDjtenqIPm7uXcXx19qmrJY-GRuCHuy4Tgo4FtBKymlBj1-g9-M6DuV3E8VZSzhnhTraUutuaXu1in6p46N6Hl8BPmwBnYwOrozQ-PSfa6nkDZueO9twf3ywjzsdsJryUyU_9ZSfWswvnoriqDcOn7L9u3Po-KAaQQVXt9eXan5N2--f5ULN6T8c4JyE</recordid><startdate>201403</startdate><enddate>201403</enddate><creator>Weiss, Dominik R.</creator><creator>Franke, D.</creator><creator>Strasser, Erwin F.</creator><creator>Ringwald, Juergen</creator><creator>Zimmermann, Robert</creator><creator>Eckstein, Reinhold</creator><general>Blackwell Publishing Ltd</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201403</creationdate><title>von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates</title><author>Weiss, Dominik R. ; Franke, D. ; Strasser, Erwin F. ; Ringwald, Juergen ; Zimmermann, Robert ; Eckstein, Reinhold</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3474-8aedc5d6a1ff94b63181c42d70ca0b13b1e0ead16fe42c5b1f99a2c97f9653bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation Factors - metabolism</topic><topic>Blood Platelets - metabolism</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Plateletpheresis</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weiss, Dominik R.</creatorcontrib><creatorcontrib>Franke, D.</creatorcontrib><creatorcontrib>Strasser, Erwin F.</creatorcontrib><creatorcontrib>Ringwald, Juergen</creatorcontrib><creatorcontrib>Zimmermann, Robert</creatorcontrib><creatorcontrib>Eckstein, Reinhold</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weiss, Dominik R.</au><au>Franke, D.</au><au>Strasser, Erwin F.</au><au>Ringwald, Juergen</au><au>Zimmermann, Robert</au><au>Eckstein, Reinhold</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2014-03</date><risdate>2014</risdate><volume>54</volume><issue>3</issue><spage>633</spage><epage>639</epage><pages>633-639</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>Background Apheresis platelet concentrates (APCs) are usually stored in citrated plasma at 22°C. The stability of coagulation proteins—von Willebrand factor (vWF), clotting factors (CFs), and their inhibitors—has often been described in association with the storage of thawed plasma. However, fewer data are available regarding changes in APCs. Study Design and Methods We measured CF activities and inhibitors in APCs on the day of manufacture (Day 0) and on Days 4, 5, and 7. vWF was determined by measuring vWF antigen (vWF:Ag) and vWF ristocetin cofactor (vWF:RCo) and by multimer analysis. Results Twenty‐one PCs obtained by plateletpheresis were studied. Major changes were observed for Factor (F)VIII (37% loss of activity within 4 days), FV (20% within 4 days), and protein S (76% within 4 days). All other CF activities remained higher than 80% over the 7 days. Fibrinogen and the inhibitors antithrombin and protein C remained quite stable. FXI, FXII, and FXIII actually increased during storage (8, 11, and 12% within 4 days). vWF:Ag increased during storage of APCs by 2% per day, with a relative loss of vWF:RCo and high‐molecular‐weight multimers. Conclusion Even after 7 days of storage at 22°C, the hemostatic potential of the plasma content in APCs was roughly preserved. The increase in FXII antigen indicates that this CF may also be stored in platelets; however, this has not yet been described.</abstract><cop>Hoboken, NJ</cop><pub>Blackwell Publishing Ltd</pub><pmid>23789907</pmid><doi>10.1111/trf.12304</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1132
ispartof Transfusion (Philadelphia, Pa.), 2014-03, Vol.54 (3), p.633-639
issn 0041-1132
1537-2995
language eng
recordid cdi_proquest_miscellaneous_1507189353
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Coagulation Factors - metabolism
Blood Platelets - metabolism
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Humans
Medical sciences
Plateletpheresis
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
von Willebrand Factor - metabolism
title von Willebrand factor, clotting factors, and clotting inhibitors in apheresis platelet concentrates
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A03%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=von%20Willebrand%20factor,%20clotting%20factors,%20and%20clotting%20inhibitors%20in%20apheresis%20platelet%20concentrates&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Weiss,%20Dominik%20R.&rft.date=2014-03&rft.volume=54&rft.issue=3&rft.spage=633&rft.epage=639&rft.pages=633-639&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.12304&rft_dat=%3Cproquest_pubme%3E3242132271%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505482554&rft_id=info:pmid/23789907&rfr_iscdi=true